Dr. (Col) MADHU BHADURIA (M04451)
Abstract
Glaucoma leads to irreversible blindness. It affects nearly 2% population above the age of 40 years. Quality glaucoma treatment is available mostly in tertiary care hospitals . These institutions are covering not more than 30% population . Hence strategy is needed to address the rest 70% population for management of glaucoma from door step to primary care to secondary care and finally and it’s linkage with tertiary care centres. This course is designed to build quality and cost-effective methodology and protocols to address glaucoma management from their door steps by Community Workers , fine tune vision centres and outreach camps. Optimization of secondary and tertiary care hospitals to suit the need of this subset of populaion. Effective integration of telemedicine and technology to facilitate this process will be dealt in this course.This can lead to optimum glaucoma treatment for all along with effective management of existing infrastructure with minimal modifications.
| 1 | Utilization and training of Community level workers to suspect and refer glaucoma (12 mins) | Dr. (Col) MADHU BHADURIA | watch video |
| 2 | Steps to enhance glaucoma detection at vision centre (10 mins) | Dr. DUBEY SUNEETA | watch video |
| 3 | Use to Technology for glaucoma detection in Outreach (10 mins) | Dr. SHIVANI DIXIT | watch video |
| 4 | Optimization of Secondary centres for management of Primary Adult Glaucoma (10 mins) | Dr.Maj Gen (Mrs ) Sagarika Patyal | watch video |
| 5 | Role of tele- ophthalmology and technology for quality cost effective glaucoma care (10 mins) | Dr.Prabhudesai Medha Nitin | watch video |
| 6 | Modification of Glaucoma care for outstation patients of glaucoma in a tertiary care hospital (10 mins) | Dr. KIRTI SINGH | watch video |
| 7 | Effective linkage of all levels and advocacy (8 mins) | Dr. (Col) MADHU BHADURIA | No Video |
| 8 | Keynote Address by Dr Nathan Congdon : Vision interventions to improve work productivity in India: the PROSPER studies (10 mins) | Dr.Nathan Congdon | watch video |
| Panel Discussion : (5 mins.) |


Leave a Comment